Clinical trial
A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage
NCT00168896 · Charite University, Berlin, Germany, Other · Unknown status
Key facts
| NCT number | NCT00168896 |
|---|---|
| Title | A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage |
| Official title | A Randomised Phase II/III Study to Compare the Combination of Carboplatin Plus Irinotecan Vs. the Combination of Carboplatin Plus Etoposide for SCLC in Extensive Disease Stage |
| Lead sponsor | Charite University, Berlin, Germany, Other |
| Collaborators | Pfizer Industry Aventis Pharmaceuticals |
| Status | Unknown status |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Carboplatin plus Irinotecan vs Carboplatin plus Etoposide |
| Enrollment | 286 |
| Start date | Oct 1, 2001 |
| Completion | Dec 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Feb 14, 2006 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: